3.9 C
Saturday December 3rd, 2022
- publicity -

Anjac Health & Beauty strengthens in North America and its pharmaceutical activities

Anjac Health & Beauty (Anjac) has announced the acquisition of Pillar5 Pharma (Pillar5), one of the leading manufacturers (CDMO) specializing in the production of sterile ophthalmic solutions and solid forms (tablets, capsules, etc.) of niches. This operation confirms Anjac's international expansion and expands its health offer with a new ophthalmic offer to serve local and international brands and laboratories. This is Anjac's second major operation in 2022 following the merger with Apollo Healthcare last January.

Pillar5, CDMO, a leading player in the sterile ophthalmology market in North America.

A Canadian-born company, Pillar5 is one of North America's leading CDMOs for the production of sterile ophthalmic solutions and solid forms (tablets, capsules, etc.) A pioneer, Pillar5 is the only CDMO to offer innovative ophthalmic solutions on the North American market, namely sterile multidoses without preservatives.

An independent company since 2009, Pillar5, based in Arnprior, Ontario, offers a full range of services from product formulation and manufacturing and packaging customization to technical services. With a diversified and loyal customer portfolio, Pillar5 supports major pharmaceutical companies in addition to ophthalmic care specialists.

The company has 150 employees and a turnover of 50M $CAD.

A unique entrepreneurial dynamism

The Anjac group signs with Pillar5 its 9th acquisition in five years and sees its global turnover reach nearly 650 million euros as a result of this operation, a doubling in the space of three years. Each new acquisition represents an opportunity for the Anjac Group to expand its service offering in specific areas, while enhancing their complementarities. The Anjac group now brings together 14 expert companies, with 22 R&D and manufacturing sites.

"We are delighted with this strategic acquisition, which allows us to develop in a new key segment, the ophthalmic market and more particularly this high value-added innovation that is sterile, multi-dose ophthalmic solutions without preservatives," explains Aurélien Chaufour, President of the Anjac Group.

"We are delighted to join a family-owned industrial group that will support us in our ambitious expansion plans. We are already identifying synergies, including commercial synergies with international customers who can be supported by Pillar5 and other companies in the Anjac Group," said Dwight Gorham, President and CEO of Pillar5.

External resources

Related articles

Our latest issue

Listen to us!


Charles River offers new articles and a webinar on his dedicated page!I am looking that up !